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1. Introduction  
Head and neck cancers refers to cancer arising in the head or neck regions including 
parnasal sinuses, nasal cavity, nasopharynx, oral cavity, salivary gland, oropharynx, 
pharynx, hypopharynx, larynx, and lymph node. Histologically, squamous cell carcinoma is 
the predominant form. The cancer progenitor cells are premalignant cells in the mucosa 
layer of head and neck. Cumulative genetic and epigenetic alterations lead to behavioural 
changes from hyperplasia to invasive carcinoma. Head and neck squamous cell carcinoma 
(HNSCC) is the sixth most common cancer worldwide. It is the 4th most common cancer 
among men in the European Union (Black et al., 1997). In United State, over 12,000 patients 
died from HNSCC every year (Altekruse et al., 2008). Globally, there are approximately 
650,000 new cases of HNSCC and 350,000 patients dying from HNSCC annually (Parkin et 
al., 2005). Most patients will develop local-regional disease with cervical lymph node 
involvements. HNSCC is heterogeneous in nature. Early disease might not have any 
symptoms. Further, the inconspicuous locations of some HNSCC make it difficult to be 
identified at the early stages. Thus, patients arrive at the clinic by large present late and have 
poor prognosis. The overall survival rate of HNSCC patients is about 50% (Stell, 1989; 
Argiris et al, 2004). Development of local recurrence, distant metastasis and secondary 
primary tumor is also common in HNSCC. Despite the advances of cancer treatment in last 
several decades, the overall survival rate of HNSCC did not have much improvement (Stell, 
1989; Argiris and Eng, 2003).  
HNSCC is a multifactorial disease. Major risk factors are alcohol consumption and tobacco 
use (Jaber et al., 1999). HNSCC is particularly common in countries with high alcohol and 
tobacco consumption e.g. southern Africa, Australia, Brazil, France, India, The Netherlands, 
Papua-New Guinea and Switzerland (Parkin et al., 2005). Smoking and drinking habit is 
associated with early onset of HNSCC (Farshadpour et al., 2007). Patients with alcohol and 
tobacco use generally have poor prognosis and poor survival rate (Farshadpour et al., 2011). 
Other risk factors of HNSCC include age, environmental exposures (including UV exposure 
and viral infection such as Epstein-Barr Virus and Human Papilloma Virus), sex, hygiene, 
industrial inhalants, and gender (Argiris et al., 2003). Regional lymph node involvement is 
also an indicator of poor prognosis. About 20–50% N0 patients will develop nodal 
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metastasis. The overall survival rate reduced to 50% in case if lymph node metastasis is 
observed (von Buchwald et al., 2002).  
Management of HNSCC is based primarily on the tumor locations and stages (Akervall, 
2005). For early HNSCC (stage I and II) surgical resection together with radiotherapy is the 
primary treatment regime. For advanced disease (stage III and IV) multidisciplinary 
treatment including surgery, radiation and chemotherapy is adopted (Posner, 2010). For 
loco-regionally advanced HNSCC, concurrent chemo-radiotherapy is used in case where the 
tumor is unresectable or adverse functional loss will be resulted from the operation (Wong 
et al., 2011). For oral squamous cell carcinoma, surgical excision of the primary tumor 
and/or selective neck dissection is the major treatment (Bilde et al., 2006). For pharyngeal 
and laryngeal SCC, radiotherapy and/or concomitant chemotherapy are commonly used 
(Lajer et al., 2011). It has been shown that the use of concomitant chemo- and radio-therapy 
is more effective in advanced HNSCC (Robbins, 2005).  
2. MicroRNA  
MicroRNA are small non-protein-coding RNA, which regulate mRNA at post-
transcriptional level. MicroRNA are small epigenetic regulators usually about 19–22 or 19–
25 nucleotides long (Ambrose, 2004). They are highly conserved molecules among different 
species including nematode, drosophila, vertebrate, and human indicating its significance in 
cellular functions. MicroRNA was first discovered in 1993 in nematode Ceanorhabditis elegans 
(C. elegans) (Lee et al., 1993). Later, the tumor suppressing microRNA let-7 was identified in 
C. elegans and mammalian models. By then, it was proposed that microRNA had a trans-
regulatory role through direct binding to the target mRNA. Computational prediction 
suggested that microRNA are regulating about 30% of human genes (Lewis et al., 2005). Up 
till now (1 July 2011), 16,772 microRNA are reported in the miRBase (see miRBase at 
http://www.mirbase.org, Release 17) at which 8.9% (1,492) are human microRNA. 
MicroRNA could bind to the target mRNA in a partial or complete complementary manner. 
They regulate gene expression by promoting target mRNA degradation and/or hindering 
mRNA translation (Bushati and Cohen, 2007).  
MicroRNA are transcribed in genomic DNA. The genes encoding microRNA are located 
throughout the human genome in intron, exon, coding / non-coding genes (Lee et al., 2002). 
MicoRNA are first transcribed by RNA polymerase II into long precursor microRNA. This 
long RNA will be cleaved by Dorsha (RNase III-type nuclease in the nucleus) generating 
primary microRNA (60–70 nucleotides hairpin molecules). The primary microRNA are later 
exported into the cytoplasma by Exportin-5 (a Ras-GTP-dependent dsRNA-binding 
protein). Primary microRNA will be further processed by Dicer (RNase complex) and TRBP 
[TAR (transactivation-responsive RNA of HIV-1) RNA-binding protein] forming an 
asymmetric microRNA:microRNA* intermediate duplex (microRNA* is usually functionless 
and are degraded subsequently). This duplex molecule is then incorporated with 
Argonaute-containing RNA-induced silencing (RISC) complex forming a functional post-
transcriptional regulator (Bartel, 2004). This functional complex usually bind to the 3’ 
untranslated region of the target mRNA (Lim et al., 2005; Wightman et al., 1993). The 
complementary binding between microRNA and the target mRNA is not necessary perfect 
in order to carry out it function as negative regulator. The binding of seed sequence (2-7 
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nucleotides on the mature microRNA) of the microRNA with the target mRNA would 
suffice to induce mRNA destabilization and degradation (Filipowicz et al., 2008).  
So far, microRNA were identified as negative regulator of specific mRNA (Lim et al., 2005). 
However, recent findings suggested that microRNA might also act as gene activator. 
Vasudevan et al. demonstrated that miR369-3 could activate translation (Vasudevan et al., 
2007). Later, Place et al. observed that miR-373 could induce E-cadherin expression in 
prostate cancer cells (Place et al., 2008). MicroRNA Let-7 can induce upregulation of gene 
involved in cell cycle arrest (Vasudevan et al., 2007). Although such activating mechanisms 
are not yet clear, it revealed that many remain to be explored if we want to uncover the 
exact functions of microRNA in human cells.  
3. MicroRNA and cancers 
In comparison with the normal counterparts, cancer displays a differential microRNA 
expression patterns (Lu et al., 2005). Association between human cancers and microRNA 
dysregulation was first observed in leukemia. Downregulation of miR-15 and miR-16 was 
first discovered in peripheral blood of chronic lymphocytic leukemia (Calin et al, 2002). For 
HNSCC, study on individual microRNA was first performed by Jiang et al. in 2005 (Jiang et 
al., 2005). Later, Tran et al. performed microRNA expression profiling on head and neck 
cancer cell lines (Tran et al., 2007).  
The microRNA profile of nasopharyngeal carcinoma, oral tongue carcinoma, and laryngeal 
carcinoma are emerging in the subsequent years (Li et al., 2010; Li et al., 2011; Liu et al., 
2009; Rentoft et al., 2011; Scapoli et al., 2010). The underlying mechanism concerning 
microRNA dysregulation in head and neck cancers is not yet clear although it has been 
reported that the microRNA processing machinery is upregulated in head and neck cancers 
(Zhang et al., 2009). Zhang noticed that the microRNA processing enzymes Dicer and 
Drosha are overexpressed in salivary gland tumor (Zhang et al., 2009). Expression of Dorsha 
(micoRNA processor) will affect the phenotype of squamous epithelial cells (Muralidhar et 
al., 2011).  
4. Mechanisms of MicroRNA dysregulation in head and neck cancers 
4.1 Chromosomal rearrangement  
Chromosomal abnormalities are associated with the development of head and neck caners 
(Akervall, 2005; Gollin et al., 2001). Common chromosomal gains in HNSCC include 3q, 5p, 
7p, 8q, 9q, 11q13, and 20q. In comparison, losses of chromosomal region were frequently 
detected on 3p, 9p, 5q, 8p, 13q, 18q, and 21q. Cromer et al. reported that genes related to 
tumorigenesis and metastasis of hypopharyngeal carcinoma were located on 3q27.3, 
17q21.2-q21.31, 7q11.22-q22.1and 11q13.1-q13.3. Chromosomal rearrangement (e.g. deletion 
or translocation) will result in dysregulation of the gene on the abbreviated loci (Akervall, 
2005).  
About 50% of the microRNA are located in minimal deleted regions, minimal amplified 
regions, and breakpoint regions involved in human cancers (Calin et al., 2004). Recently, 
Persson et al., has shown that t(6;9)(q22–23;p23–24) will lead to fusion of MYB oncogene to 
the transcription factor gene NFIB in head and neck cancers (Persson et al., 2009). As the 3’-
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UTR of MYB is targeted by miR-15a/16, the chromosomal translocation allows the cancer 
cells to escape control by miR-15a/16. Lee et al., identified that miR-204 located in 9q21.1-
22.3, a cancer genomic-associated region of head and neck cancers, is linked to progression 
of HNSCC (Lee et al., 2010). Loss of heterozygosity (LOH) in these loci are common in 
HNSCC (Bauer et al., 2008; Spafford et al., 2001). 
4.2 DNA hypermethylation  
DNA hypermethylation is usually found in the CpG island of tumor suppressor genes. 
Methylation of the clustered CpG dinucleotides in the CpG island would result in 
transcriptional silencing of the genes. It is now known that the methylated CpG dinucleotide 
could also link to the regulation of microRNA expression. Promoter methylation will affect 
binding of the transcriptional machinery (Zhang et al., 2011). Demethylation treatment of 
the nasopharyngeal carcinoma cells with demethylating agents would result in let-7 
upregulation indicating the involvement of DNA methylation in regulating let-7 expression 
in nasopharyngeal carcinoma cells (Wong et al., 2011). Kozaki et al. identified that DNA 
methylation is linked to the transcriptional silencing of miR-137 and miR-193a, both of which 
are tumor suppressing microRNA associated with oral SCC (Kozaki et al, 2008). Apart from 
microRNA, the methylated microRNA promoter can also be used as a biomarker for HNSCC 
patients. Langevin et al. reported that methylated miR-137 promoter is associated with the 
clinical pathological characteristic of HNSCC patients (Langevin et al., 2010) 
4.3 Genetic polymorphism of microRNA-encoding region  
Similar to mRNA, microRNA are also encoded by genomic DNA. Theoretically, any 
variation in genomic materials will affect the biogenesis and final sequence of the mature 
microRNA (the seed sequence especially) and affect the specificity of microRNA to their 
target mRNA. Thus, any genetic variation in the microRNA biogenesis pathway gene, 
primary microRNA, precursor microRNA or mature microRNA sequence will eventually 
affect the microRNA regulatory pathways (Slaby et al., 2011) 
4.3.1 Single nucleotide polymorphism (SNP) of microRNA-encoding genes 
The association between microRNA and SNP has been demonstrated recently (Duan et al., 
2007). It has already been demonstrated that SNP will affect the processing of pre-
microRNA (Yu et al., 2007). In HNSCC, SNP of miRNA-146a (rs2910164; guanine to 
cytosine), miR-149 (rs2292832; guanine to thymine), miR-196a2 (rs11614913), and miR-499 
(rs3746444; adenine to guanine) are associated with the risk of developing HNSCC (Liu et al 
2010). Christensen et al. confirmed the association of SNP in miR-196a2 (rs11614913, C/T) 
with HNSCC. They demonstrated that miR-196a2 polymorphism is associated with the risk 
of HNSCC (Christensen et al., 2010). 
4.3.2 Single nucleotide polymorphism (SNP) of microRNA-targeted genes 
Apart from microRNA itself, SNP on microRNA target genes will also affect the binding 
efficacy of microRNA. Zhang et al. demonstrated that SNP associated with microRNA 
biogenesis pathway genes and microRNA-targeted genes are associated with the prognosis 
of HNSCC patients (Zhang et al., 2010). They proposed that microRNA-related genetic 
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polymorphisms might be used as predicative markers for secondary primary and/or 
recurrence in early HNSCC patients (Zhang et al., 2010).  
4.4 MicroRNA dysregulation by candidate oncogene  
MicroRNA expression could be controlled by oncogene such as myc. He et al. reported that 
the miR-17-92 cluster is transactivated by myc (He et al., 2007). In addition, p53 is also 
shown to be involved in microRNA dysregulation through inducing miR-34 expression 
(Chang et al., 2008; He et al., 2005; Melo and Estella, 2011; Suzuki et al., 2009). 
5. MicroRNA as molecular markers in circulation and body fluids in HNSCC  
With the advance of molecular techniques and understanding in cancers, molecular markers 
are now considered as an effective auxiliary test in conjunction to histological examination 
in assisting clinical decision making (Hui et al., 2010). The existence of differential 
microRNA patterns between cancer and the normal counterparts opens up the possibility of 
using the differential expressed microRNA in monitoring cancers (Krutovskikh et al., 2010). 
In view of the myriad of functions of microRNA in cancers, de Planell-Saguer and Rodicio 
suggested that microRNA is potentially useful as biomarkers for cancer onset, prognosis, 
risk of diseases and cancer classification (de Planell-Saguer and Rodicio, 2011).  
MicroRNA is suitable cancer marker as it is highly stable and is resistant to degradation (Li 
et al., 2007). Significant amount of extracellular microRNA had been detected in peripheral 
blood, urine, saliva and semen (Mitchell et al., 2008; Hanke et al., 2009; Park et al., 2009; 
Zubakov et al., 2010) making it a candidate biomarker for detection and surveillance of 
HNSCC in a non-invasive manner. In addition, it could be extracted in formalin-fixed 
paraffin-embedded tissues (Li et al., 2007). Circulating microRNA have been found to be 
significantly elevated in the peripheral blood of head and neck cancer patients. However, 
there is no direct evidence showing that primary tumor is the only source of the circulating 
microRNA. Reduction of the circulating microRNA after removal of the primary tumor 
suggested that primary tumor is one of the major sources of circulating microRNA (Iguchi et 
al., 2010; Kosaka et al., 2010).  
Peripheral blood has high RNase activity, however, circulating microRNA could still exist in 
cell-free form and remain stable in the blood (Mitchell et al., 2008). Circulating microRNAs 
are existed in membrane-bound vesicles (about 50 nm to 1 um) and are released from the 
cancer cells through exocytosis (Février & Raposo, 2004; Heijnen et al., 1999; Hunter et al., 
2008). Recently, Turchinovich et al. performed physical analysis on the characteristics of the 
circulating microRNA. They noticed that circulating microRNA could exist independently 
without the vesicle provided that they are bound to the Ago2 protein (Turchinovich et al., 
2011).  
6. Examples of microRNA dysregulation in HNSCC  
Depending on the functions, the dysregulated microRNA could be classified into oncogenic 
microRNA (onco-miR) and tumor suppressing microRNA (Kozaki et al., 2008; Iorio et al., 
2005). Identifying the dysregulated microRNA patterns in HNSCC is useful in selecting 
suitable microRNA biomarkers for use in HNSCC monitoring (Chang et al., 2008; Ferdin et 
www.intechopen.com
 
Squamous Cell Carcinoma 
 
260 
al., 2010). We here performed a review on the potential oncogenic microRNA and tumor 
suppressing microRNA identified in HNSCC.  
6.1 Let-7 Family 
Human let-7 has multiple isoforms. They are let-7a-1[Mature sequence: 6 - 
ugagguaguagguuguauaguu – 27 (MI0000060)], let-7a-2 [Mature sequence: 5 - 
ugagguaguagguuguauaguu – 26 (MI0000061)], let-7a-3 [Mature sequence: 4 - 
ugagguaguagguuguauaguu – 25 (MI0000062)], let-7b [Mature sequence: 6 - 
ugagguaguagguugugugguu – 27 (MI0000063)], let-7c [Mature sequence: 11 - 
ugagguaguagguuguaugguu – 32 (MI0000064)], let-7d [Mature sequence: 8 - 
agagguaguagguugcauaguu – 29 (MI0000065), let-7e (Mature sequence: 8 - 
ugagguaggagguuguauaguu – 29 (MI0000066), let-7f-1 [Mature sequence: 7 - 
ugagguaguagauuguauaguu – 28 (MI0000067)], let-7f-2 [Mature sequence: 8 - 
ugagguaguagauuguauaguu – 29 (MI0000068)], let-7g (Mature sequence: 5 - 
ugagguaguaguuuguacaguu – 26 (MI0000433)], and let-7i [Mature sequence: 6 - 
ugagguaguaguuugugcuguu – 27 (MI0000434).  
In human cancers, expression of let-7 family is usually reduced suggesting its tumor-
suppressing role. In comparison with the normal nasopharyngeal cells, let-7 levels were 
significantly decreased in the nasopharyngeal carcinoma. Reduced expression levels of let-7 
(-a, -b, -d, -e, -g, and -i) were detected in nasopharyngeal carcinoma cells compared to 
normal nasopharyngeal cells. Ectopic expression of let-7 in nasopharyngeal carcinoma cells 
reduced cell proliferation (Wong et al., 2011). Moreover, c-Myc expression was inhibited in 
NPC cells transfected with precursor let-7 (Wong et al., 2011). Association of let-7 with cell 
proliferation was also observed in oral cancer cells (Jakymiw et al. 2010). Let-7a microRNA 
expression was inhibited in both laryngeal squamous cancer tissues and in laryngeal cancer 
cell lines (Hep-2 and BEAS-2B). Let-7a could inhibit proliferation and induce apoptosis in 
laryngeal carcinoma cells (Long et al., 2009). In Hep-2 cells, overexpression of let-7a could 
also suppress RAS and c-MYC protein expression (Long et al., 2009). It was demonstrated 
that up-regulated RAS and c-MYC protein levels had inverse correlation with the down-
regulated let-7a levels in cancer tissues (Long et al., 2009). Further, let-7a could enhance the 
chemosensitivity of head and neck cancer cells and might link to the stemness gene 
expression pathway (Yu et al., 2011).  
6.2 MiR-15a [Mature sequence: 14 - uagcagcacauaaugguuugug - 35 (MI0000069)] 
Regulation of miR-15a is altered in head and neck cancer cells (Persson et al. 2009). 
Expression of miR-15a was inversely correlated with protein kinase C which was usually 
overexpressed in primary HNSCC (Cohen et al., 2009). It has been shown that 
overexpression of miR-15a suppressed cyclin E protein expression and inhibition of miR-15a 
enhanced cyclin E protein expression in laryngeal cancer cell line. Precursor miR-15a could 
also affect DNA synthesis in laryngeal carcinoma cells but the related mechanisms are not 
yet identified (Cohen et al., 2009). These results indicated that miR-15a might function as a 
tumor suppressor through regulating the gene associated with the proliferation pathways of 
cancer cells (Cohen et al., 2009). 
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6.3 MiR-21 [Mature sequence: 8 - uagcuuaucagacugauguuga - 29 (MI0000077)] 
Overexpression of miR-21 was first reported in human glioblastoma and miR-21 is now 
recognized as an potent anti-apoptotic factor (Fu et al., 2011). Upregulation of miR-21 is 
observed in multiple human cancers including breast, cervical, colon, leukemia, liver, lung, 
ovarian, pancreas, prostate, stomach and thyroid as well as head & neck (Krichevsky et al., 
2009; Volinia et al., 2006). Elevated expression of miR-21 is observed in tongue squamous 
cell carcinomas. Suppressing miR-21 in tongue SCC cell lines (SCC-15 and CAL27) reduced 
cell survival and induced apoptosis (Li et al., 2009). It has been found that the expression 
level of miR-21 was reversely correlated with TPM1. The observation suggested that miR-21 
may inhibit cell apoptosis partly via silencing the expression of TPM1 (Li et al., 2009). 
Furthermore, it has been shown that miR-21 expression was an independent prognostic 
factor associated with survival rate (Li et al., 2009). Moreover, repeated injection of miR-21 
antisense oligonucleotide could inhibit tumor formation in nude mice (Li et al., 2009). 
Laryngeal cancer cell line (JHU-O11) transfected with miR-21 displayed enhanced cell 
growth (Chang et al., 2008).  
6.4 MiR-29 [Mature sequence: 54 - uagcaccauuugaaaucgguua – 75 (MI0000735)] 
MiR-29c expression was suppressed in nasopharyngeal carcinomas in comparison with 
normal healthy nasopharyngeal epithelia (Sengupta et al., 2008). The function of miR-29c is 
not yet clear. In HeLa cells, transfection of miR-29c precursor could suppress expression of 
collagen 3A1, 4A1, 15A1, laminin, and thymine-DNA glycosylase (TDG) linking to tumor 
cell invasiveness and metastatsis (Sengupta et al., 2008).  
6.5 MiR-100 [Mature sequence: 13 - aacccguagauccgaacuugug - 34 (MI0000102)] and 
miR-125b [Mature sequence: 15 - ucccugagacccuaacuuguga - 36 (MI0000446)] 
Suppression of both miR-100 and miR-125b were reported in HNSCC. Expression levels of 
miR-125b and miR-100 were decreased in oral squamous cell carcinoma cell lines and 
tumors of alveolar ridge, buccal mucosa, floor of mouth, retromolar trigone and tongue 
(Henson et al., 2009). Overexpression of miR-100 and miR-125b inhibited cell proliferation in 
buccal mucosa cell lines (Henson et al., 2009). Suppressed expression of miR-100 and miR-
125b in oral cancer cells may lead to cancer progression and loss of sensitivity to ionizing 
radiation (Henson et al., 2009).  
6.6 MiR-133 family  
MiR-133 has 2 isoforms: miR-133a [Mature sequence: 53 - uuugguccccuucaaccagcug – 74 
(MI0000450)] and miR-133b [Mature sequence: 66 - uuugguccccuucaaccagcua – 87 
(MI0000822)]. Downregulation of miR-133 had been reported in HNSCC including tongue 
SCC (Child et al., 2009). Decreased expression of miR-133a and miR-133b was observed in 
tongue SCC cells. Tongue SCC cell lines (Cal27, HN21B and HN96) transfected with miR-
133a and miR-133b precursors showed reduced proliferation rate and elevated apoptosis 
rate (Wong et al., 2008a). Overexpression of miR-133a and miR-133b reduced the expression 
of pyruvate kinase type M2 (PKM2) in tongue SCC cell lines (Wong et al., 2008a). The 
elevated expression of PKM2 in tongue SCC tissues was associated with the down-regulated 
expression of miR-133a and miR-133b (Wong et al., 2008a).  
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6.7 MiR-137 [Mature sequence: 59 - uuauugcuuaagaauacgcguag – 81 (MI0000454)] 
Expression of mir-137 was downregulated in tongue carcinoma cells. Ectopic expression of 
miR-137 could inhibit cell growth cell growth in tongue SCC cell line HSC-6 and HSC-7 
(Kozaki et al., 2008). MiR-137 is essential to cell cycle control of HNSCC. MiR-137 mimics 
enhanced the accumulation of G0-G1 phase cells, suggesting that it was associated with cell 
cycle arrest at the G1-S checkpoint (Kozaki et al., 2008). Expression of CDK6, E2F6, and 
NCOA2/TIF2 was suppressed by miR-137 in tongue SCC cell lines (Kozaki et al., 2008). 
Apart from the microRNA itself, the methylation status of miR-137 promoter has potential 
clinical value. Methylated miR-137 is a potential prognostic marker in HNSCC and is 
associated with survival (Langevin et al., 2011).  
6.8 MiR-138 [Mature sequence: 23 - agcugguguugugaaucaggccg - 45 (MI0000476)] 
MiR-138 is linked to cell invasion, cell cycle arrest and apoptosis of HNSCC (Liu et al. 
2009). Reduced expression of miR-138 was reported in oral tongue cell lines UM1, UM2, 
Cal27, SCC1, SCC4, SCC9, SCC15, SCC25 (Liu et al., 2009). High level of miR-138 could 
reduce migration and invasion rate of tongue cancer cell UM1 and UM2 (Jiang et al., 
2010). It has been demonstrated that overexpression of miR-138 could reduce expression 
of two key genes in the Rho GTPase signaling pathway, RhoC and ROCK2, leading to the 
reorganization of the stress fibers (Jiang et al., 2010). In contrast, inhibition the expression 
of miR-138 increased RhoC and ROCK2, contributing to an elongated cell morphology 
and enhanced cell migration and invasion (Jiang et al., 2010). The expression level of miR-
138 was inhibited in hypopharyngeal carcinoma cell line (1386Tu) and oropharyngeal 
carcinoma cell line (686Tu) compared to non-tumorigenic cells (OKF4-E6/7 and NHOK) 
(Liu et al., 2009) 
6.9 MiR-141 [Mature sequence: 59 - uaacacugucugguaaagaugg – 80 (MI0000457)] 
Dysregulation of miR-141 was observed in head and neck cancer. However, its role in the 
pathogenesis remains unknown. Enhanced miR-141 expression was observed in NPC 
specimens in comparison with normal nasopharyngeal epithelium. Suppression of miR-141 
affected cell cycle, apoptosis, cell growth, migration and invasion in NPC cells (Zhang et al., 
2010). It has been shown that miR-141 directly targeted BRD3, UBAP1 and PTEN that are 
involved in NPC carcinogenesis (Zhang et al., 2010). Furthermore, inhibition of miR-141 
affected the expression levels of some important molecules in the Rb/E2F, JNK2 and AKT 
pathways (Zhang et al., 2010). In contrast, Nurul-Syakima et al. demonstrated that miR-141 
was downregulated in HNSCC and the results were different from those observed in NPC 
(Nurul-Syakima et al., 2011). Further studies are warranted to elucidate the role of miR-141 
in head and neck cancers.  
6.10 MiR-184 [Mature sequence: 53 - uggacggagaacugauaagggu – 74 (MI0000481)] 
MiR-184 was overexpressed in early oral SCC (Cervigne et al., 2009). Cervigne et al. 
demonstrated that miR-184 was upregulated during the progression of progressive 
dysplasia and oral SCC suggesting that miR-184 might potentially be used as a biomarker 
for malignant transformation. In tongue SCC, primary tumor has higher level of miR-184 in 
comparison with the paired normal epithelial cells. Inhibition of endogenous miR-184 in 
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tongue SCC cell lines (Cal27, HN21B, and HN96) resulted in reduced cell proliferation rate 
and enhanced apoptotic rate (Wong et al., 2008b). The observations that miR-184 levels were 
increased in the plasma before operation and decreased significantly after surgical treatment 
suggested that plasma miR-184 levels might serve as biomarker in oral tongue SCC patients 
(Wong et al., 2008b).  
6.11 MiR-193a [Mature sequence 21 - ugggucuuugcgggcgagauga – 42 (MI0000487)] 
The expression of miR-193a was inhibited in buccal mucosa cell line HO-1-N-1 cell line. 
Furthermore, HO-1-N-1 cell line transfected with miR-193a mimics displayed suppressed 
cell growth and induced apoptosis (Kozaki et al., 2008). In addition, miR-193a mimics 
reduced the protein levels of E2F6 and PTK2/FAK (Kozaki et al., 2008).  
6.12 MiR-204 [Mature sequence 33 - uucccuuugucauccuaugccu – 54 (MI0000284)] 
The expression of miR-204 was suppressed in tongue SCC cell lines (SCC58, SCC61, 
SCC151) and hard palate cell line SCC135 (Lee et al., 2010). Overexpression of miR-204 
inhibited migration, adhesion and invasion of HNSCC cell (Lee et al., 2010). MiR-204 
expression was reduced in NPC cell lines JSQ3 (Nasal cavity) and SQ38 (pyriform sinus) 
compared to samples of pooled normal buccal mucosa. NPC cell lines transfected with miR-
204 mimics displayed suppressed cell-matrix interaction, motility and invasiveness (Lee et 
al., 2010). 
6.13 MiR-205 [Mature sequence: 34 - uccuucauuccaccggagucug – 55 (MI0000285)] 
MiR-205 is associated with the epithelial-mesenchymal transition of head and neck 
carcinoma (Zidar et al., 2011). It was proposed that high expression levels of miR- 205 can be 
used to detect HNSCC positive lymph nodes (Fletcher et al., 2008).  
6.14 MiR-222 [Mature sequence: 69 - agcuacaucuggcuacugggu – 89 (MI0000299)] 
MiR-222 is associated with the aggressiveness of tongue cancer cell lines (Liu et al., 2009b). 
Overexpression of miR-222 in UM1 resulted in reduced cell invasion (Liu et al., 2009b). It 
has been shown that miR-222 directly targeted metalloproteinase 1 (MMP1) and manganese 
superoxide dismutase 2 (SOD2) and suppressed their expression in oral tongue SCC cell 
lines (Liu et al., 2009b). These results indicated that miR-222 may serve as a novel 
therapeutic target for oral tongue SCC patients (Liu et al., 2009b).  
6.15 Others microRNA dysregulation  
It was recently shown that the expression levels of miR-221 to miR-375 could be used to 
distinguish tumor from normal tissue with high specificity and sensitivity (Avissar et al., 
2009). The expression levels of miR-196b, miR-138, miR-155, miR-142-3p, and miR-18a were 
elevated and expression levels of miR-204, miR-449a, miR-34c-3p, miR-143, and miR-145 
were reduced in NPC samples in comparison with normal nasopharyngeal tissues (Chen et 
al., 2009). Several biological pathways including TGF-Wnt pathways, G1-S cell cycle 
progression, VEGF signaling pathways, apoptosis and survival pathways, and IP3 signaling 
pathways are targeted by these down-regulated microRNA (Chen et al., 2009).  
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Tumor  
sites 
Sub-sites  MicroRNA Dysregulation Related 
functions 
 References 
oral cavity 
carcinoma 
alveolar 
ridge 
miR-100 
miR-125b 
down-regulated 
down-regulated 
proliferation 
proliferation 
(Henson et al., 2009) 
(Henson et al., 2009) 
 buccal 
mucosa 
miR-100 
miR-125b 
miR-193a  
down-regulated 
down-regulated 
down-regulated 
proliferation 
proliferation 
growth 
(Henson et al., 2009) 
(Henson et al., 2009) 
(Kozaki et al., 2008) 
 floor of 
mouth 
miR-100 
miR-125b 
miR-138 
down-regulated 
down-regulated 
down-regulated 
proliferation 
proliferation 
migration, 
invasion 
(Henson et al., 2009) 
(Henson et al., 2009) 
(Jiang et al., 2010; 
Liu et al., 2009a) 
 hard palate miR-204 down-regulated migration, 
invasion 
(Lee et al., 2010) 
 retromolar 
trigone 
miR-100 
miR-125b 
down-regulated 
down-regulated 
proliferation 
proliferation 
(Henson et al., 2009) 
(Henson et al., 2009) 
 tongue miR-100 
miR-125b 
miR-138 
miR-184 
miR-204 
miR-222 
miR-21 
miR-133a 
miR-133b 
miR-137 
down-regulated 
down-regulated 
down-regulated 
up-regulated 
down-regulated 
down-regulated 
up-regulated 
down-regulated 
down-regulated 
down-regulated 
proliferation 
proliferation 
migration, 
invasion 
apoptosis, 
proliferation 
migration, 
invasion 
invasion 
apoptosis, 
survival 
proliferation, 
apoptosis 
proliferation, 
apoptosis 
growth 
(Henson et al., 2009) 
(Henson et al., 2009) 
(Henson et al., 2009; 
Liu et al., 2009a) 
(Wong et al., 2008b) 
(Lee et al., 2010) 
(Liu et al., 2009b) 
(Li et al., 2009) 
(Wong et al., 2008a) 
(Wong et al., 2008a) 
(Kozaki et al., 2008) 
naso 
pharyngeal 
carcinoma 
 miR-196b 
miR-138 
miR-155  
miR-142-3p 
miR-18a 
miR-204  
miR-449a 
miR-34c-3p 
miR-143  
miR-145 
let-7 family
miR-29c 
miR-141 
miR-204 
up-regulated 
up-regulated 
up-regulated 
up-regulated 
up-regulated 
down-regulated 
down-regulated 
down-regulated 
down-regulated 
down-regulated 
down-regulated 
down-regulated 
up-regulated 
down-regulated 
 
proliferation 
metastasis 
apoptosis, 
invasion 
migration, 
invasion 
(Chen et al., 2009) 
(Chen et al., 2009) 
(Chen et al., 2009) 
(Chen et al., 2009) 
(Chen et al., 2009) 
(Chen et al., 2009) 
(Chen et al., 2009) 
(Chen et al., 2009) 
(Chen et al., 2009) 
(Chen et al., 2009) 
(Wong et al., 2011) 
(Sengupta et al., 
2008) 
(Zhang et al., 2010) 
(Lee et al., 2010) 
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Tumor  
sites 
Sub-sites  MicroRNA Dysregulation Related 
functions 
 References 
pharyngeal 
carcinoma 
oropharynx miR-138 down-regulated  (Liu et al., 2009a) 
 hypo 
pharynx 
miR-138 down-regulated  (Liu et al., 2009a) 
laryngeal 
carcinoma 
 miR-let-7a 
miR-204 
miR-21 
miR-15a 
down-regulated 
down-regulated 
up-regulated 
down-regulated 
Proliferation, 
apoptosis 
migration, 
invasion 
growth 
proliferation 
(Long et al., 2009) 
(Lee et al., 2010) 
(Chang et al., 2008) 
(Cohen et al., 2009) 
Table 1. MicroRNA dysregulation in HNSCC 
7. The role of viral-encoded microRNA in head and neck cancers 
7.1 Epstein-Barr Virus (EBV) 
EBV is a member of gamma-Herpes virus and is closely associated with the progression of 
undifferentiated nasopharyngeal carcinoma (Wei and Sham, 2005). EBV is the first identified 
oncogenic virus. Expression of EBV-encoded oncoproteins are linked to epithelial-
mesenchymal transition of metastatic nasopharyngeal carcinoma (HoriKawa et al., 2011). 
EBV could alter somatic gene expression by controlling the microRNA biogenesis machinery 
of the host cells. Li et al. observed that LMP1 could induce expression of miR-10b and 
promote metastasis of nasopharyngeal carcinoma cells (Li et al., 2010). Du et al. reported that 
EBV oncoprotein LMP1 and LMP2A could activate miR-155 expression in nasopharyngeal 
carcinoma cells which is associated with the nodal status and metastasis of nasopharyngeal 
carcinoma patients (Du et al., 2011).  
Apart from the viral oncoprotein, the microRNA encoded by EBV virus itself is also playing 
a part in pathogenesis of nasopharyngeal carcinoma cells. EBV-encoded microRNA was first 
discovered in 2004 (Pfeffer et al., 2004). At present, 25 precursors and 44 mature microRNA 
were identified (Sanger database Release 16). The identified EBV microRNA are encoded in 
2 major clusters: BHRF1 cluster and BART cluster (Lung et al., 2009). Barth et al. 
demonstrated that EBV-BART2 could target EBV DNA polymerase BALF5 hindering the 
lytic replication of EBV (Barth et al., 2008). EBV-encoded microRNA could regulate the 
activity of EBV and enhance the survival of the host cells (Lo et al., 2007). For example, 
BART5-5p could target pro-apoptotic gene PUMA contributing to the resistance to apoptotic 
agents (Choy et al., 2008). 
As mentioned above, expression of the EBV oncoprotein LMP1 (Key viral oncoprotein 
linked to the pathogenesis of nasopharyngeal carcinoma) is critical in the pathogenesis of 
nasopharyngeal carcinoma. LMP1 act as tumor necrosis factor receptor (TNFR). It is the 
activator in multiple cancer-related pathways and could enhance proliferation, migration, 
and cell cycle progression in nasopharyngeal carcinoma cells (Kung et al., 2011). It is now 
known that LMP1 expression is partly controlled by the EBV-encoded microRNA. Lo et al. 
demonstrated that BART1-5p, BART16-5p and BART17-5p are involved in the regulation of 
LMP1 in nasopharyngeal carcinoma cells (Lo et al., 2007). In addition, LMP1 can suppress 
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somatic gene expression by inducing somatic microRNA expression (Anastasiadou et al., 
2011; Motsch et al., 2007).  
7.2 Human Papilloma Virus (HPV) 
HPV is a DNA virus and could infect squamous epithelial cells (Muno et al., 2003; Tran et 
al., 2007). HPV infection was closely associated with cervical cancer and account for 70% of 
the cervical cancers (No et al., 2011). Recent data suggested that it could also play a role in 
HNSCC. In general, HPV could be found in about 30% of the HNSCC. According to Heller 
and Münger, HPV is associated with 24% oral cavity cancer and 36% in oropharynx cancer 
(Hellner and Münger, 2011). HPV infection has also been reported in nasopharyngeal 
carcinoma (Lo et al., 2010). Increasing evidence suggested that HPV is closely associated 
with tonsillar cancer with prevalence ranged from 50-100% (Hammarstedt et al., 2006; 
Nasman et al., 2009; Syrjanen, 2004). Alcohol and tobacco consumption is linked to the risk 
of HPV infection (Chaturvedi et al., 2008; Tran, 2007). HPV status greatly influences the 
clinical features and prognosis of head and neck cancer patients (Lajer and Buchwald, 2010). 
The viral-encoded oncoprotein is a sensitive and specific marker for identifying tonsillar 
carcinoma patients (Hellner and Münger, 2011).  
HPV-infected HNSCC cells had a different microRNA expression pattern in comparison 
with the HPV-negative counterpart (Wald et al., 2011; Wang et al., 2008). It is now clear that 
HPV could affect the host microRNA expression patterns resulting in the distinct clinical 
features (Lajer and Buchwald, 2010). Similar to EBV, HPV-encoded microRNA could 
modulate the microRNA expression machinery of the host (Wang et al., 2009). Lajer et al. 
reported that HPV infection is closely associated with the alteration of miR-127-3p and 
miR363 in oral and pharyngeal SCC (Lajer et al., 2011). By interfering the E6-p53 and E7-pRb 
pathways, HPV E6 and E7 oncoproteins could control expression of miR-15/16 cluster, miR-
17-92 family, miR-21, miR-23b, miR-34a, and miR-106b/93/25 cluster in the host cells 
(Zheng and Wang, 2011).  
By the time of writing, there is still no HPV-encoded microRNA reported and its role is 
largely unknown. In addition, the oncogenic role of HPV is affected by geographic factors 
(Lajer et al., 2010). The prevalence of HPV-associated HNSCC varies between different 
geographic regions. Low prevalence is reported in Asia, Central Europe, and Latin America 
(Kreimer et al., 2005; Ribeiro et al., 2011). HPV is nearly undetectable in tonsillar carcinoma 
of the Chinese patients (Li et al., 2003). The data suggested that HPV infection is a risk factor 
for a subset of HNSCC and the molecular pathways associated with HPV-negative HNSCC 
remain to be elucidated.  
8. Methods used in microRNA detection  
Similar to gene expression patterns, head and neck cancers had specific microRNA 
expression patterns. With microRNA profiling, Lu et al. could distinguish poorly 
differentiated carcinoma from the rest (Lu et al., 2005). Thus, there is a need to develop 
molecular techniques to (1) detect and quantify known microRNA; and (2) identify novel 
microRNA; and (3) perform global and high throughput microRNA profiling. Since 
identification of the first microRNA in C. elegan, the technologies employed to examine 
microRNA are fast evolving. The following session will briefly describe the common 
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methods used in microRNA research. Among all the method, northern blotting is nearly the 
first use to detect and quantify specific microRNA expression (Lau et al., 2001). To date, this 
technique is largely replaced by others in detecting and quantifying microRNA. In situ 
hybridization detection is used to monitor the cellular and subcellular distribution of 
microRNA (Wienholds et al., 2005). In situ hybridization could be used on both frozen 
section and on archival formalin-fixed paraffin-embedded (FFPE) allowing localization of 
microRNA in clinical specimens. Real-time quantitative PCR is now the most commonly 
used technique in detecting and quantifying microRNA of interest. With the growing 
number of microRNA sequence published in the miRBase, real-time quantitative PCR 
primers and probe set could be designed to amplify specific microRNAs. For high 
throughout microRNA profiling, different form of microRNA array are commercially 
available. The oligo-nucleotide arrays allow detection of the whole miRBase library in a 
single run and are very suitable to use in examining the expression patterns of samples (Liu 
et al., 2008). Recently, next generation sequencing (deep sequencing) is employed to identify 
novel microRNA. The technique allows sequencing of the whole genome within weeks. In 
addition, deep sequencing can be used to identify posttranscriptional modifications in 
mature microRNAs. Initial studies have suggested that these post-transcriptionally 
modified, so-called isomiRs, might be evidence of tissue-specific or even tumor-specific 
distribution (Lee et al., 2010; Kunchenbauer et al., 2008). Commonly used system for 
microRNA identification includes Solexa (Illumina), SOLiD (ABI), and 454 (Roche) which 
allows detection of microRNA in low abundance (Fridlander et al., 2008).  
9. MicroRNA and epigenetic therapies 
MicroRNA could target multiple gene transcripts making it a good choice for systemic 
therapy of cancers. The rationale of microRNA-based therapy is similar to siRNA-based 
therapy. Based on the gene sequence, the microRNA/siRNA of a target gene could be 
synthesized chemically and delivered to the cancer patients. Synthetic microRNA can be 
used to restore the levels of basal tumor suppressing microRNA in cancer cells. In addition, 
microRNA antagonist (partially or completely complementary to specific microRNA 
sequences) can be designed based on the mature microRNA sequence to inhibit the 
overexpressed oncogenic microRNA in cancer cells (Krutzfeldt et al., 2005). The therapeutic 
microRNA could be packed into microvesicles and delivered to the cancer sites directly or 
through the circulation system (Skog et al., 2008). Cancer cell could take up the 
microvesicles at high efficiency as the constituent of microvesicle are similar to the plasma 
membrane (Thery et al., 2002). Elmén et al. tested this idea using mouse models and non-
human primate models [African green monkeys (Chlorocebus aethiops)] (Elmén et al., 2008). 
They synthesized the miR-122 antagonist and delivered it into the animal model. MiR-122 is 
related to the cholesterol mechanisms in liver cells. The miR-122 antagonist could be taken 
by the liver cells resulting in decreased plasma cholesterol levels without any toxicity. 
Similar to drug treatment, the major challenge of microRNA-based therapy is the efficiency 
to deliver the therapeutic microRNA to cancer tissues as microvesicle in circulation is 
actively cleaned up by macrophage and kidney. Further, large microvesicles are difficult to 
pass through the capilliary endothelium and extracellular matrix of head and neck tissues 
(Bader et al., 2011). Advances in the microRNA delivery system are necessary in order to 
put microRNA-based therapy into clinical practice. 
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10. Concluding remarks 
HNSCC is a complex disease caused by accumulating genetic, epigenetic and proteomic 
alterations. MicroRNA is a potent regulator controlling multiple biological processes 
including cell growth, differentiation, cell death, development and immune responses (Flynt 
et al., 2008; Stefani et al., 2008; Lodish et al., 2008). With emerging data supporting that 
microRNA plays a central role in gene dysregulation in human malignancies, unraveling the 
microRNA expression patterns in different HNSCC is essential and critical if we want to 
develop better diagnostic and prognostic system for our patients. On the other hand, 
gaining better insight into the regulatory mechanisms of microRNA would allow us to 
design therapeutic regime, which targets the disease with better outcome. We could 
anticipate that our knowledge to HNSCC will be changed with the increase in 
understanding of microRNA in the coming decades. Translating our knowledge into clinical 
management will be a beneficial to the treatment and prognosis of our patients.  
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